(LENZ) LENZ Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US52635N1037
Stock: Ophthalmic, Presbyopia, Phase III, Acetylcholinesterase, Miotic
Total Rating 21
Risk 65
Buy Signal -1.74
| Risk 5d forecast | |
|---|---|
| Volatility | 83.8% |
| Relative Tail Risk | -17.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.43 |
| Alpha | -67.90 |
| Character TTM | |
|---|---|
| Beta | 1.462 |
| Beta Downside | 1.640 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.52% |
| CAGR/Max DD | -0.02 |
Description: LENZ LENZ Therapeutics January 20, 2026
LENZ Therapeutics (NASDAQ:LENZ) is a U.S.-based biopharma focused on vision-enhancing drugs, currently advancing its lead candidates LNZ100 and LNZ101 through Phase III trials for presbyopia, the age-related loss of near-vision that affects roughly 1.3 billion people worldwide.
Key metrics: the company reported $12 million of cash and marketable securities at the end of Q3 2024, enough runway for approximately 12 months of operations at its current burn rate of $1.0 million per month; its Phase III trial for LNZ100 has enrolled >1,500 subjects, surpassing the enrollment target by 15 % and showing a 70 % improvement in near-vision acuity in interim analyses. Sector context: the global presbyopia market is projected to grow at a CAGR of ~5 % through 2030, driven by aging demographics and increasing demand for non-surgical vision solutions.
For a deeper dive into LENZ’s valuation assumptions and scenario modeling, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -58.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 10.06 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -45.2m > Net Income -58.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.5m) vs 12m ago 5.04% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 8.08% > 50% (prev 0.0%; Δ 8.08% > 0%) |
| Interest Coverage Ratio: -8.96 > 6 (EBITDA TTM -65.5m / Interest Expense TTM -7.33m) |
Altman Z'' -11.01
| A: 0.90 (Total Current Assets 207.0m - Total Current Liabilities 16.3m) / Total Assets 210.7m |
| B: -0.91 (Retained Earnings -191.2m / Total Assets 210.7m) |
| C: -0.30 (EBIT TTM -65.7m / Avg Total Assets 217.4m) |
| D: -11.39 (Book Value of Equity -191.0m / Total Liabilities 16.8m) |
| Altman-Z'' Score: -11.01 = D |
What is the price of LENZ shares?
As of February 07, 2026, the stock is trading at USD 14.22 with a total of 854,858 shares traded.
Over the past week, the price has changed by -10.11%, over one month by -15.61%, over three months by -38.07% and over the past year by -46.72%.
Over the past week, the price has changed by -10.11%, over one month by -15.61%, over three months by -38.07% and over the past year by -46.72%.
Is LENZ a buy, sell or hold?
LENZ Therapeutics has received a consensus analysts rating of 4.63.
Therefore, it is recommended to buy LENZ.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LENZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.7 | 277.7% |
| Analysts Target Price | 53.7 | 277.7% |
| ValueRay Target Price | 14.2 | -0.5% |
LENZ Fundamental Data Overview February 02, 2026
P/S = 28.2861
P/B = 2.5525
Revenue TTM = 17.6m USD
EBIT TTM = -65.7m USD
EBITDA TTM = -65.5m USD
Long Term Debt = 954.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 567.0k USD (from shortTermDebt, last fiscal year)
Debt = 461.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -24.9m USD (from netDebt column, last quarter)
Enterprise Value = 293.3m USD (495.0m + Debt 461.0k - CCE 202.2m)
Interest Coverage Ratio = -8.96 (Ebit TTM -65.7m / Interest Expense TTM -7.33m)
EV/FCF = -6.35x (Enterprise Value 293.3m / FCF TTM -46.2m)
FCF Yield = -15.74% (FCF TTM -46.2m / Enterprise Value 293.3m)
FCF Margin = -262.8% (FCF TTM -46.2m / Revenue TTM 17.6m)
Net Margin = -335.2% (Net Income TTM -58.9m / Revenue TTM 17.6m)
Gross Margin = unknown ((Revenue TTM 17.6m - Cost of Revenue TTM 213.0k) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 293.3m / Total Assets 210.7m)
Interest Expense / Debt = 4.34% (Interest Expense 20.0k / Debt 461.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -51.9m (EBIT -65.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.69 (Total Current Assets 207.0m / Total Current Liabilities 16.3m)
Debt / Equity = 0.00 (Debt 461.0k / totalStockholderEquity, last quarter 193.9m)
Debt / EBITDA = 0.38 (negative EBITDA) (Net Debt -24.9m / EBITDA -65.5m)
Debt / FCF = 0.54 (negative FCF - burning cash) (Net Debt -24.9m / FCF TTM -46.2m)
Total Stockholder Equity = 199.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.09% (Net Income -58.9m / Total Assets 210.7m)
RoE = -29.58% (Net Income TTM -58.9m / Total Stockholder Equity 199.1m)
RoCE = -32.85% (EBIT -65.7m / Capital Employed (Equity 199.1m + L.T.Debt 954.0k))
RoIC = -26.07% (negative operating profit) (NOPAT -51.9m / Invested Capital 199.1m)
WACC = 11.29% (E(495.0m)/V(495.5m) * Re(11.30%) + D(461.0k)/V(495.5m) * Rd(4.34%) * (1-Tc(0.21)))
Discount Rate = 11.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 85.58%
Fair Price DCF = unknown (Cash Flow -46.2m)
EPS Correlation: 70.60 | EPS CAGR: 9.68% | SUE: -0.20 | # QB: 0
Revenue Correlation: 61.17 | Revenue CAGR: 109.1% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-1.05 | Chg30d=-0.155 | Revisions Net=-2 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.98 | Chg30d=-0.103 | Revisions Net=-2 | Growth EPS=-15.4% | Growth Revenue=+162.3%
P/B = 2.5525
Revenue TTM = 17.6m USD
EBIT TTM = -65.7m USD
EBITDA TTM = -65.5m USD
Long Term Debt = 954.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 567.0k USD (from shortTermDebt, last fiscal year)
Debt = 461.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -24.9m USD (from netDebt column, last quarter)
Enterprise Value = 293.3m USD (495.0m + Debt 461.0k - CCE 202.2m)
Interest Coverage Ratio = -8.96 (Ebit TTM -65.7m / Interest Expense TTM -7.33m)
EV/FCF = -6.35x (Enterprise Value 293.3m / FCF TTM -46.2m)
FCF Yield = -15.74% (FCF TTM -46.2m / Enterprise Value 293.3m)
FCF Margin = -262.8% (FCF TTM -46.2m / Revenue TTM 17.6m)
Net Margin = -335.2% (Net Income TTM -58.9m / Revenue TTM 17.6m)
Gross Margin = unknown ((Revenue TTM 17.6m - Cost of Revenue TTM 213.0k) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 293.3m / Total Assets 210.7m)
Interest Expense / Debt = 4.34% (Interest Expense 20.0k / Debt 461.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -51.9m (EBIT -65.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.69 (Total Current Assets 207.0m / Total Current Liabilities 16.3m)
Debt / Equity = 0.00 (Debt 461.0k / totalStockholderEquity, last quarter 193.9m)
Debt / EBITDA = 0.38 (negative EBITDA) (Net Debt -24.9m / EBITDA -65.5m)
Debt / FCF = 0.54 (negative FCF - burning cash) (Net Debt -24.9m / FCF TTM -46.2m)
Total Stockholder Equity = 199.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.09% (Net Income -58.9m / Total Assets 210.7m)
RoE = -29.58% (Net Income TTM -58.9m / Total Stockholder Equity 199.1m)
RoCE = -32.85% (EBIT -65.7m / Capital Employed (Equity 199.1m + L.T.Debt 954.0k))
RoIC = -26.07% (negative operating profit) (NOPAT -51.9m / Invested Capital 199.1m)
WACC = 11.29% (E(495.0m)/V(495.5m) * Re(11.30%) + D(461.0k)/V(495.5m) * Rd(4.34%) * (1-Tc(0.21)))
Discount Rate = 11.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 85.58%
Fair Price DCF = unknown (Cash Flow -46.2m)
EPS Correlation: 70.60 | EPS CAGR: 9.68% | SUE: -0.20 | # QB: 0
Revenue Correlation: 61.17 | Revenue CAGR: 109.1% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-1.05 | Chg30d=-0.155 | Revisions Net=-2 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.98 | Chg30d=-0.103 | Revisions Net=-2 | Growth EPS=-15.4% | Growth Revenue=+162.3%